Dopamine D2 receptor blockade needed for the treatment of schizophrenia

Research output: Contribution to journalReview article

Abstract

For most antipsychotics, positron emission tomography studies have demonstrated that a therapeutic window of striatal D2 receptor occupancy (65-80%) is associated with clinical response in young adults with schizophrenia. On the other hand, the dopamine D2 receptor occupancy required for the maintenance of remission may be lower than that for acute phase treatment. A series of our modeling work has shown that the dose needed to achieve a target dopamine D2/3 receptor occupancy at peak and trough can be estimated for each individual. First, striatal dopamine D2 receptor occupancy levels with antipsychotics such as risperidone and olanzapine can be predicted from plasma antipsychotic concentrations. Second, doses that result in any given target plasma levels at any point in time can be estimated, using plasma levels of those drugs with two sparsely collected plasma samples with population pharmacokinetic techniques. Furthermore, we demonstrated that by combining these two models, doses that correspond to any given dopamine D2/3 receptor occupancy with risperidone and olanzapine can be reliably estimated for each individual. Thus, in practice, the dose needed to achieve a target D2 receptor blockade at peak and trough can be estimated for each individual and therefore could be used as a target dose.

Original languageEnglish
Pages (from-to)127-131
Number of pages5
JournalJapanese Journal of Neuropsychopharmacology
Volume37
Issue number5-6
Publication statusPublished - 2017 Nov 1

Fingerprint

Dopamine D2 Receptors
olanzapine
Schizophrenia
Antipsychotic Agents
Corpus Striatum
Risperidone
Therapeutics
Positron-Emission Tomography
Young Adult
Pharmacokinetics
Maintenance
Pharmaceutical Preparations
Population

Keywords

  • Antipsychotics
  • Dopamine
  • Dopamine receptor
  • Schizophrenia

ASJC Scopus subject areas

  • Clinical Psychology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Dopamine D2 receptor blockade needed for the treatment of schizophrenia. / Uchida, Hiroyuki.

In: Japanese Journal of Neuropsychopharmacology, Vol. 37, No. 5-6, 01.11.2017, p. 127-131.

Research output: Contribution to journalReview article

@article{7ed35bfeae114c51864cf722942db1ac,
title = "Dopamine D2 receptor blockade needed for the treatment of schizophrenia",
abstract = "For most antipsychotics, positron emission tomography studies have demonstrated that a therapeutic window of striatal D2 receptor occupancy (65-80{\%}) is associated with clinical response in young adults with schizophrenia. On the other hand, the dopamine D2 receptor occupancy required for the maintenance of remission may be lower than that for acute phase treatment. A series of our modeling work has shown that the dose needed to achieve a target dopamine D2/3 receptor occupancy at peak and trough can be estimated for each individual. First, striatal dopamine D2 receptor occupancy levels with antipsychotics such as risperidone and olanzapine can be predicted from plasma antipsychotic concentrations. Second, doses that result in any given target plasma levels at any point in time can be estimated, using plasma levels of those drugs with two sparsely collected plasma samples with population pharmacokinetic techniques. Furthermore, we demonstrated that by combining these two models, doses that correspond to any given dopamine D2/3 receptor occupancy with risperidone and olanzapine can be reliably estimated for each individual. Thus, in practice, the dose needed to achieve a target D2 receptor blockade at peak and trough can be estimated for each individual and therefore could be used as a target dose.",
keywords = "Antipsychotics, Dopamine, Dopamine receptor, Schizophrenia",
author = "Hiroyuki Uchida",
year = "2017",
month = "11",
day = "1",
language = "English",
volume = "37",
pages = "127--131",
journal = "Japanese Journal of Neuropsychopharmacology",
issn = "1343-4144",
publisher = "Japanese Society of Neuropsychopharmacology",
number = "5-6",

}

TY - JOUR

T1 - Dopamine D2 receptor blockade needed for the treatment of schizophrenia

AU - Uchida, Hiroyuki

PY - 2017/11/1

Y1 - 2017/11/1

N2 - For most antipsychotics, positron emission tomography studies have demonstrated that a therapeutic window of striatal D2 receptor occupancy (65-80%) is associated with clinical response in young adults with schizophrenia. On the other hand, the dopamine D2 receptor occupancy required for the maintenance of remission may be lower than that for acute phase treatment. A series of our modeling work has shown that the dose needed to achieve a target dopamine D2/3 receptor occupancy at peak and trough can be estimated for each individual. First, striatal dopamine D2 receptor occupancy levels with antipsychotics such as risperidone and olanzapine can be predicted from plasma antipsychotic concentrations. Second, doses that result in any given target plasma levels at any point in time can be estimated, using plasma levels of those drugs with two sparsely collected plasma samples with population pharmacokinetic techniques. Furthermore, we demonstrated that by combining these two models, doses that correspond to any given dopamine D2/3 receptor occupancy with risperidone and olanzapine can be reliably estimated for each individual. Thus, in practice, the dose needed to achieve a target D2 receptor blockade at peak and trough can be estimated for each individual and therefore could be used as a target dose.

AB - For most antipsychotics, positron emission tomography studies have demonstrated that a therapeutic window of striatal D2 receptor occupancy (65-80%) is associated with clinical response in young adults with schizophrenia. On the other hand, the dopamine D2 receptor occupancy required for the maintenance of remission may be lower than that for acute phase treatment. A series of our modeling work has shown that the dose needed to achieve a target dopamine D2/3 receptor occupancy at peak and trough can be estimated for each individual. First, striatal dopamine D2 receptor occupancy levels with antipsychotics such as risperidone and olanzapine can be predicted from plasma antipsychotic concentrations. Second, doses that result in any given target plasma levels at any point in time can be estimated, using plasma levels of those drugs with two sparsely collected plasma samples with population pharmacokinetic techniques. Furthermore, we demonstrated that by combining these two models, doses that correspond to any given dopamine D2/3 receptor occupancy with risperidone and olanzapine can be reliably estimated for each individual. Thus, in practice, the dose needed to achieve a target D2 receptor blockade at peak and trough can be estimated for each individual and therefore could be used as a target dose.

KW - Antipsychotics

KW - Dopamine

KW - Dopamine receptor

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85044360657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044360657&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:85044360657

VL - 37

SP - 127

EP - 131

JO - Japanese Journal of Neuropsychopharmacology

JF - Japanese Journal of Neuropsychopharmacology

SN - 1343-4144

IS - 5-6

ER -